Updated Recommendation
A new evidence synthesis was published:2025, WHO updated recommendations on HIV clinical management: recommendations for a public health approach
View latest version (2025)Bibliographic Info
Recommendation
Recommended in favor
Conditional
Certainty of evidence
Moderate
dolutegravir (DTG) in combination with an optimized nucleoside reverse-transcriptase inhibitor backbone is recommended as the preferred second-line regimen for people living with HIVa for whom non-DTGbased regimens are failing
Also Featured In
This recommendation also appears in the following guidelines:
Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV
Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach